- Home
- REFI vs VNDA Comparison
REFI vs VNDA Comparison
Compare REFI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- VNDA
- Stock Information
- Founded
- REFI 2021
- VNDA 2002
- Country
- REFI United States
- VNDA United States
- Employees
- REFI N/A
- VNDA N/A
- Industry
- REFI Real Estate Investment Trusts
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- VNDA Health Care
- Exchange
- REFI Nasdaq
- VNDA Nasdaq
- Market Cap
- REFI 304.4M
- VNDA 261.7M
- IPO Year
- REFI 2021
- VNDA 2006
- Fundamental
- Price
- REFI $14.25
- VNDA $4.97
- Analyst Decision
- REFI Strong Buy
- VNDA Strong Buy
- Analyst Count
- REFI 3
- VNDA 3
- Target Price
- REFI $20.00
- VNDA $15.33
- AVG Volume (30 Days)
- REFI 105.4K
- VNDA 417.8K
- Earning Date
- REFI 08-06-2025
- VNDA 07-30-2025
- Dividend Yield
- REFI 13.19%
- VNDA N/A
- EPS Growth
- REFI N/A
- VNDA N/A
- EPS
- REFI 1.88
- VNDA N/A
- Revenue
- REFI $56,790,054.00
- VNDA $201,351,000.00
- Revenue This Year
- REFI $15.53
- VNDA $16.86
- Revenue Next Year
- REFI $6.70
- VNDA $39.78
- P/E Ratio
- REFI $7.58
- VNDA N/A
- Revenue Growth
- REFI 4.68
- VNDA 13.37
- 52 Week Low
- REFI $12.76
- VNDA $3.81
- 52 Week High
- REFI $16.47
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- REFI 48.62
- VNDA 67.29
- Support Level
- REFI $13.85
- VNDA $4.66
- Resistance Level
- REFI $14.59
- VNDA $4.95
- Average True Range (ATR)
- REFI 0.29
- VNDA 0.15
- MACD
- REFI 0.01
- VNDA 0.03
- Stochastic Oscillator
- REFI 51.76
- VNDA 89.39
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.